Shire acquires Noven's MethyPatch; Noven reacquires rights
Shire Pharmaceuticals (central nervous system, cancer, and anti-infective drugs) has acquired Noven Pharmaceuticals' (transdermal drug delivery) MethyPatch (methylphenidate), a once-daily patch to treat attention deficit hyperactivity disorder (ADHD), which has been awaiting FDA approval since June 2002.
- Specialty Pharmaceuticals
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
- Product Purchase
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.